

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 39

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Riverview Health</p> <p>2. 395 Westfield Road P.O. Box 220 Noblesville, IN 46060</p>	<p>In accordance with the letter dated March 16, 2016</p> <p>3. License number 13-16286-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date October 31, 2020</p> <hr/> <p>5. Docket No. 030-10729 Reference No.</p>
------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed one curie of I-131)
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 200 millicuries total

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. In vitro studies.

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 395 Westfield Road, Noblesville, Indiana.
- 11. The Radiation Safety Officer for this license is Phillip R. Partlan, R.T.
- 12. Licensed Material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-16286-01Docket or Reference Number
030-10729**Amendment No. 39**

B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Anthony J. Cossell, M.D.	10 CFR 35.100, 35.200, and 31.11.
William E. McGraw, M.D.	10 CFR 35.100 and 35.200.
John Mark Michael, M.D.	10 CFR 35.100, 35.200, and 35.300.
Richard L. Hallett, M.D.	10 CFR 35.100, 35.200, and 35.300.
Peter D. Arfken, M.D.	10 CFR 35.100, 35.200, and 35.300.
John A. Morton, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Margaret Brengle, M.D.	10 CFR 35.100 and 35.200.
Jeffrey I. Reider, M.D.	10 CFR 35.100 and 35.200.
Homer F. Beltz, M.D.	10 CFR 35.100 and 35.200.
Michael S. Skulski, M.D.	10 CFR 35.100 and 35.200.
Richard T. Beeler, M.D.	10 CFR 35.100, 35.200, and 35.300.
Steven A. Fritsch, M.D.	10 CFR 35.100 and 35.200.
Frank J. Pistoia, M.D.	10 CFR 35.100 and 35.200.
Michael A. Kuharik, M.D.	10 CFR 35.100 and 35.200.
Janalyn P. Ferguson, M.D.	10 CFR 35.100 and 35.200.
Jane S. Mitchell, M.D.	10 CFR 35.100 and 35.200.
Jack J. Moss, M.D.	10 CFR 35.100 and 35.200.
Lori J. Wells, M.D.	10 CFR 35.100 and 35.200.
Eric D. Elliott, M.D.	10 CFR 35.100 and 35.200.
Charles A. Lerner, M.D.	10 CFR 35.100 and 35.200.
Thomas Hagman, M.D.	10 CFR 35.100, 35.200, and 35.300.
Brian J. Weigel, M.D.	10 CFR 35.100, 35.200, and 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-16286-01

Docket or Reference Number
030-10729

Amendment No. 39

<u>Authorized Users</u>	<u>Material and Use</u>
Jack M. Drew, M.D.	10 CFR 35.100, 35.200, and 35.300.
David R. Gulliver, M.D.	10 CFR 35.100, 35.200, and 35.300.
J. Michael Phelps, Jr., M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Timothy L. David, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Theodore P. Labus, M.D.	10 CFR 35.100, 35.200, and 35.300.
Cristina N. Shinaver, M.D.	10 CFR 35.100, 35.200, and 35.300.
Edward R. Bartley, M.D.	10 CFR 35.100 and 35.200.
Caryn Cockerill Anderson, M.D.	10 CFR 35.100 and 35.200.
Warren Kent Hansen, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Carlo Robert Lazzaro, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Charles C. Mulry, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Eric E. Beltz, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Laura Dugan, M.D.	10 CFR 35.100 and 35.200.
Jonathan Kahn, M.D.	10 CFR 35.100, 35.200, and 35.300.
Parin Bhayani, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-16286-01

Docket or Reference Number
030-10729

Amendment No. 39

Authorized Users

Material and Use

Matthew M. Jones, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

Matthew Locker, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 27, 2010 (ML101241072).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date APR 28 2016

By William P. Reichhold
William P. Reichhold
Materials Licensing Branch
Region III